May 29th 2025
Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.
Charleston, W.V., tops market for diabetes meds purchases
April 2nd 2007Charleston, W.V., is the market with the highest incidence of people who purchased medicine for diabetes over the past year, according to Scarborough Research. Of consumers in this market, 15% are diabetes medication purchasers, followed by Knoxville, Tenn. (14%), Memphis (11%), Columbus, Ohio (11%), and Tulsa, Okla. (11%).
FDA commissioner backs a third class of drugs
April 2nd 2007DA Commissioner Andrew C. von Eschenbach, M.D., recently told a group of attendees of the Consumer Healthcare Product Association's annual executive conference in Naples, Fla., that in order to increase consumer access to healthcare products, stakeholders should explore "new ways that might include the opportunity to think through and pursue the process of a third class of drugs regulated by FDA."
Pharmacy schools must meet new stringent standards
April 2nd 2007ACPE will be more rigorous in reviewing Pharmacy schools for accreditation. The change is spurred in part by the Department of Education, which surveys ACPE. Thanks to a more demanding DOE, ACPE put two pharmacy schools on probation recently.
New report covers how to advance personalized medicine
April 2nd 2007HHS has released a 128-page report on realizing the promise of pharmacogenomics (PGx). The report discusses, among other issues, the educational needs of pharmacists, physicians, and other health professionals; PGx tests sold over the counter in drugstores; and the liability to M.D.s and R.Ph.s from off-label use of PGx.
FDA issues final rule for OTC laxative drug products
April 2nd 2007FDA is issuing a final rule establishing that over the counter laxative drug products in granular dosage form containing the bulk-forming ingredients psyllium (hemicellulose), psyllium hydrophilic mucilloid, psyllium seed, psyllium seed (blond), psyllium seed husks, plantago ovata husks, and plantago seed are not generally recognized as safe and effective and are misbranded.
Latebreakers: Breast cancer agent gets green light
April 2nd 2007Patients with HER2-positive advanced or metastatic breast cancer whose disease has progressed following treatment with an anthracycline, a taxane, and trastuzumab (Herceptin, Genentech) will now have a new therapeutic option. Lapatinib (Tykerb, GlaxoSmithKline) has been approved by the FDA for use in combination with capecitabine (Xeloda, Roche) following a priority review.
Drug patent expirations (2007-2009)
April 2nd 2007The next several years are expected to be sweet for the generic drug industry and rather bitter for brand pharmaceutical companies as they gear up to defend numerous patent challenges. This is a list of brand pharmaceuticals that will lose their patents through 2009.